Results 131 to 140 of about 19,002 (159)

Two-year outcomes of intravitreal ziv-aflibercept

British Journal of Ophthalmology, 2018
Aim To assess the two-year outcome of intravitreal ziv-aflibercept (IVZ) in eyes with macular diseases. Methods Consecutive subjects with various macular diseases that received six or more of 0.05 mL IVZ (1.25 mg) injections with at ...
Ahmad M Mansour, Mohammed Ashraf, Abdulrazzak Charbaji, Muhammad H Younis, Ahmed A Souka, Avantika Dogra, Hana A Mansour, Jay Chhablani   +7 more
openaire   +3 more sources

Safety of 5914 intravitreal ziv-aflibercept injections [PDF]

British Journal of Ophthalmology, 2018
PurposeTo analyse the pooled safety data of intravitreal ziv-aflibercept (IVZ) therapy for various retinal conditions.MethodsThis was a retrospective, observational study which included patients from 14 participating centres who received IVZ. The medical records of patients who received IVZ from March 2015 through October 2017 were evaluated.
Sumit Randhir Singh, Michael W Stewart, Goura Chattannavar, Mohammed Ashraf, Ahmed Souka, Mazen ElDardeery, Neeraj Wadhwa, Chintan Sarvaiya, Ahmad M Mansour, Ameen Marashi, Suresh Ramchandani, Imoro Zeba Braimah, Mohammad Hossein Jabbarpoor Bonyadi, Alireza Ramezani, Masoud Soheilian, João Rafael de Oliveira Dias, Gabriel Costa de Andrade, André Maia, Eduardo Büchele Rodrigues, Michel Eid Farah, Alay Banker, Jay Chhablani   +21 more
openaire   +3 more sources

Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy [PDF]

British Journal of Ophthalmology, 2018
AimTo assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases.MethodsIn this prospective study, consecutive subjects received intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections for various macular diseases. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the
Ahmad M, Mansour, Abdulrazzak, Charbaji, Michel Eid, Farah, Hana A, Mansour, Jay, Chhablani   +4 more
openaire   +3 more sources

Regression of Inflamed Pterygia by Frequent High-Dose Intralesional Ziv-Aflibercept [PDF]

Cornea, 2017
Purpose: Intralesional single low-dose vascular endothelial growth factor antagonists have traditionally failed in causing regression of pterygia. The current pilot study investigates the role of high-dose repeated intralesional ziv-aflibercept in causing regression of inflamed or recurring pterygia.
Mansour, Ahmad Mohammed Farid Mahmoud
openaire   +3 more sources

Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes

Ophthalmic Surgery, Lasers and Imaging Retina, 2018
BACKGROUND AND OBJECTIVE: To study the safety and efficacy of intravitreal injections of ziv-aflibercept (IVI-ZA) (Zaltrap; Sanofi-Aventis and Regeneron Pharmaceuticals, Tarrytown, NY) during a period of 48 weeks in patients with diabetic macular edema (DME).
Gabriel Costa, de Andrade, João Rafael, de Oliveira Dias, André, Maia, Michel Eid, Farah, Carsten H, Meyer, Eduardo Buchele, Rodrigues   +5 more
openaire   +3 more sources

Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA

Medical Oncology, 2017
Routine clinical practice data often differ from clinical trials. This study describes real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) receiving ziv-aflibercept in non-academic, community oncology ...
Mei Sheng Duh, Jasmina Ivanova, Francis Vekeman   +2 more
exaly   +2 more sources

Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections [PDF]

Seminars in Ophthalmology, 2020
Purpose: To report the ocular and systemic adverse events in eyes receiving ≥10 intravitreal ziv-aflibercept (IVZ) injections. Methods: Medical records of patients who received ≥10 IVZ for various chorioretinal conditions with minimum follow up period of
Ahmad Mansour, Imoro Zeba Braimah
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Ziv-aflibercept (Zaltrap) for the Treatment of Metastatic Colorectal Cancer

Annals of Pharmacotherapy, 2013
Objective: Review pharmacology, pharmacokinetics, efficacy, and safety of ziv-aflibercept in combination with FOLFIRI for treatment of metastatic colorectal cancer (mCRC) resistant to or progressed following oxaliplatin-containing regimens. Data Sources: Articles indexed in PubMed (1948-August 2013), TOXLINE (2001-August 2013), and Google Scholar as ...
Scott L, Perkins, Sabrina W, Cole
openaire   +2 more sources

SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT

Retina, 2016
To evaluate the safety of intravitreal ziv-aflibercept (Zaltrap) in the treatment choroidal neovascularization secondary to age-related macular degeneration.Eligible eyes with choroidal neovascularization secondary to age-related macular degeneration each received a single intravitreal injection of ziv-aflibercept. Comprehensive ophthalmic examinations
Jay, Chhablani, Raja, Narayanan, Annie, Mathai, Rohit, Yogi, Michael, Stewart   +4 more
openaire   +2 more sources

SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT

Retina, 2017
Purpose: To evaluate the safety of single intravitreal 2 mg ziv-aflibercept (0.08 mL) injections for the treatment of choroidal neovascular membranes (CNVM). Methods: Eyes with choroidal neovascular membranes because of several ...
Jay, Chhablani, Chintan Jethalal, Dedhia, Hari K, Peguda, Michael, Stewart   +3 more
openaire   +2 more sources